Rapport Therapeutics, Inc. Common Stock (RAPP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.47B
Last updated: Nov 17, 2026 at 4:15 PM ET
Rapport Therapeutics, Inc. Common Stock (RAPP) Statistics
Rapport Therapeutics, Inc. Common Stock (RAPP) has a market cap of $1.47B and an enterprise value of $1.40B. Revenue grew 2677.78% over the last 12 months from the 12 months before. It kept -752.35% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 5.08% below the market cap, as cash exceeds debt.
| Market Cap | $1.47B |
|---|---|
| Enterprise Value | $1.40B |
| Latest price (Nov 17, 2026) | $23.76 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 56.7x and 2.9x.
| P/S Ratio | 56.7x |
|---|---|
| Forward P/S | 73.5x |
| P/B Ratio | 2.9x |
Price Statistics
The stock is down 2.50% over 52 weeks and trades 23.50% below its 50-day average.
| Beta (1Y) | 1.34 |
|---|---|
| 52-Week Change | -2.50% |
| 1-Month Change | -16.92% |
| 3-Month Change | -51.58% |
| 6-Month Change | -30.87% |
| Total Return (1Y) | -2.50% |
| Return vs SPY (1Y) | -17.72% |
| Max Drawdown (1Y) | -57.14% |
| Max Drawdown (3Y) | -75.54% |
| Sharpe Ratio (1Y) | -0.10 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $31.06 |
| 200-Day Average | $35.56 |
| 52-Week Range | $22.06 to $52.93 |
| RSI (14 Days) | 38.5 |
| Average Volume (20 Days) | 1.26M |
Financial Position
Current assets cover 20.07x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 20.07x |
|---|---|
| Quick Ratio | 20.07x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -38.46% and return on assets is -35.95% over the last 12 months.
| Return on Equity (ROE) | -38.46% |
|---|---|
| Return on Assets (ROA) | -35.95% |
| Asset Turnover | 0.04x |
| Receivables Turnover | 86.21x |
Scores
RAPP has an Altman Z-Score of 23.54, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 23.54 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $20.00M over the last 12 months.
| Revenue | $20.00M |
|---|---|
| Revenue Growth (YoY) | +2677.78% |
| Gross Profit | $19.73M |
| Operating Income | -$167.62M |
| Pretax Income | -$150.47M |
| Net Income | -$150.47M |
| Reported EPS (TTM) | -$3.17 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.46% of the $418.56M in total assets.
| Cash and Equivalents | $74.75M |
|---|---|
| Total Debt | $0 |
| Net Cash | $74.75M |
| Net Cash Per Share | $1.56 |
| Working Capital | $387.08M |
| Shareholder Equity | $391.19M |
| Book Value Per Share | $8.19 |
| Total Assets | $418.56M |
| Total Liabilities | $27.37M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$120.85M |
|---|---|
| FCF Per Share | -$2.10 |
| Depreciation and Amortization | $3.39M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -838.08%.
| Gross Margin | 98.67% |
|---|---|
| Operating Margin | -838.08% |
| Pretax Margin | -752.35% |
| Net Margin | -752.35% |
Peer Position
Against 7 similar companies, RAPP has the 4th highest P/S.
P/S RatioPeer median 21.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -59.47%
| P/S Ratio | 56.7x vs 21.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +2677.78% vs -59.47% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About RAPP
What is RAPP's market cap?
Rapport Therapeutics, Inc. Common Stock has a market cap of $1.47B. Its enterprise value, which adds debt and subtracts cash, is $1.40B.
How many shares of RAPP are outstanding?
Rapport Therapeutics, Inc. Common Stock has 47.77M shares outstanding. The count is up 25.94% from a year earlier.
Does RAPP pay a dividend?
No. Rapport Therapeutics, Inc. Common Stock does not pay a dividend.
How much debt does RAPP have?
Rapport Therapeutics, Inc. Common Stock has $0 of total debt and $74.75M of cash and equivalents, a net cash position of $74.75M.
RAPP pages: Overview, Charting, Earnings, Forecast, Statistics, Competitors